RNA virus inhibitor compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-12186309-B2
Application number	US-202217950785-A
Country	US
Kind code	B2
Filing date	Sep 22, 2022
Priority date	Sep 27, 2021
Publication date	Jan 7, 2025
Grant date	Jan 7, 2025

Abstract

The present disclosure provides compounds and methods for inhibiting a virus infection, such as a Baltimore Group IV RNA virus infection. Aspects of the present disclosure also include methods of treating a Baltimore Group IV RNA virus infection in a subject. The present disclosure also provides pharmaceutical compositions related to the same.

First claim

What is claimed is:

1. A compound of formula II:

wherein:
R 6 is selected from —CH 3 and —CHF 2 ;
each R 7 is independently selected from —H, -D and —CH 3 , or together two R 7 and the carbon they are attached to form a cyclopropyl group; and
Z is selected from —CH 2 CH 2 CH 2 — and —C(CH 3 ) 2 —;
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

2. The compound of claim 1 , wherein the compound is selected from the following structures:

3. A method of inhibiting a Baltimore Group IV RNA virus in a cell infected with a Baltimore Group IV RNA virus, the method comprising contacting the cell with a compound of claim 1 .

4. The method of claim 3 , wherein the Baltimore Group IV RNA virus is selected from picornavirus, norovirus, and coronavirus.

5. The method of claim 4 , wherein the Baltimore Group IV RNA virus is selected from enterovirus, rhinovirus, coxsackie virus, norovirus and coronavirus.

6. The method of claim 5 , wherein the Baltimore Group IV RNA virus is coronavirus.

7. The method of claim 6 , wherein the coronavirus is one that causes disease in mammals.

8. The method of claim 7 , wherein the coronavirus causes disease in companion animals or livestock.

9. The method of claim 8 , wherein the coronavirus is a feline coronavirus.

10. The method of claim 9 , wherein the coronavirus is feline infectious peritonitis.

11. The method of claim 7 , wherein the coronavirus is a human coronavirus.

12. The method of claim 11 , wherein the coronavirus is selected from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), Severe Acute Respiratory syndrome coronavirus 1 (SARS-CoV-1) and Middle Eastern Respiratory syndrome-related coronavirus (MERS-CoV).

13. A method of treating a Baltimore Group IV RNA virus infection in a mammal, the method comprising administering to the mammal an effective amount of a compound according to claim 1 .

14. The method of claim 13 , wherein the mammal is selected from a companion animal and livestock.

15. The method of claim 14 , wherein the mammal is a feline.

16. The method of claim 13 , wherein the mammal is a human.

17. The method of claim 13 , wherein the Baltimore Group IV RNA virus is selected enterovirus, rhinovirus, coxsackie virus, norovirus and coronavirus.

18. The method of claim 17 , wherein the Baltimore Group IV RNA virus is selected from norovirus, and coronavirus.

19. The method of claim 18 , wherein the Baltimore Group IV RNA virus is human norovirus.

20. The method of claim 18 , wherein the Baltimore Group IV RNA virus is a coronavirus that causes disease in mammals.

21. The method of claim 20 , wherein the coronavirus is a feline coronavirus.

22. The method of claim 21 , wherein the feline coronavirus is feline infectious peritonitis.

23. The method of claim 20 , wherein the coronavirus is a human coronavirus.

24. The method of claim 23 , wherein the human coronavirus is selected from Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), Severe Acute Respiratory syndrome coronavirus 1 (SARS-CoV-1) and Middle Eastern Respiratory syndrome-related coronavirus (MERS-CoV).

Assignees

• Univ Alberta

Inventors

• Nieman James A
• Lemieux M Joanne
• Tyrrell D Lorne
• Hena Mostofa
• Kandadai Appan Srinivas
• Belovodskiy Alexandr
• Joyce Michael A
• Arutyunova Elena

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61K31/454 Primary

  containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone · CPC title